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Abstract 
Vascular endothelial growth factor (VEGF) signaling is tightly regulated by 
specific VEGF receptors (VEGF-R). Recently, we identified heterodimerisation 
between VEGFR-1 and VEGFR-2 (VEGFR1-2) to regulate VEGFR-2 function. 
However, both the mechanism of action and the relationship with VEGFR-1 
homodimers remain unknown. The current study shows that activation of 
VEGFR1-2, but not VEGFR-1 homodimers, inhibits VEGFR-2 receptor 
phosphorylation under VEGF stimulation in human endothelial cells. 
Furthermore, inhibition of phosphatidylinositol 3-kinase (PI3K) increases 
VEGFR-2 phosphorylation under VEGF stimulation. More importantly, 
inhibition of PI3K pathway abolishes the VEGFR1-2 mediated inhibition of 
VEGFR-2 phosphorylation. We further demonstrate that inhibition of PI3K 
pathway promotes capillary tube formation. Finally, the inhibition of PI3K 
abrogates the inhibition of in vitro angiogenesis mediated by VEGFR1-2 
heterodimers. These findings demonstrate that VEGFR1-2 heterodimers and 
not VEGFR-1 homodimers inhibit VEGF-VEGFR-2 signaling by suppressing 
VEGFR-2 phosphorylation via PI3K pathway.  
(138 words) 
Key words: Vascular endothelial growth factor (VEGF), VEGF Receptors, 
heterodimers, phosphatidylinositol 3-kinase (PI3K), angiogenesis 
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Introduction 
 
Patients with ischemic limb and cardiac disease suffer from vascular 
insufficiencies. There is, therefore, a need to increase blood flow and promote 
functional collateral circulation in these patients.  The discovery of vascular 
endothelial growth factor (VEGF) as a stimulator of blood vessel formation 
provided a new avenue for the treatment of vascular insufficiencies. The 
VEGF signaling pathway promotes angiogenesis [1]. The major ligand VEGF-
A binds to and activates VEGFR-1, VEGFR-2 and VEGFR1-2 receptors. Unlike 
VEGF-A, placental growth factor (PlGF-1) specifically activates VEGFR-1, but 
not neuropilin or VEGFR-2, thus serves a unique tool for studying VEGFR-1 
signaling (Fig. 1A) [2, 3]. Although PlGF-1 was demonstrated to regulate inter- 
and intramolecular cross talk between the VEGFR-1 and VEGFR-2, this 
regulation is mediated through an indirect pathway rather than direct binding 
to VEGFR-2 [4]. Similarly, VEGF-E, a virus-origin VEGF homologue, 
exclusively binds to and activates VEGFR-2, and not VEGFR-1 or VEGFR-3 
(Fig. 1A) [5, 6, 7]. However, no natural ligands are identified that activate 
VEGFR1-2 without activating VEGFR-1 homodimers.    
 
The VEGF signaling pathway is tightly regulated as the process of 
angiogenesis regulates blood vessel formation and wound healing, and 
dysregulation leads to tumor growth and ischemic disease [8, 9, 10, 11]. 
VEGF-A levels are maintained within a narrow concentration range to ensure 
successful function [11, 12]. A soluble form of VEGFR-1 (sFlt-1) acts as a 
natural antagonist to VEGF-A and PlGF-1 to suppress VEGF signaling [13, 
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14]. Prior to the development of tools to study VEGFR1-2 heterodimer function, 
it was reported that VEGFR-1 receptor acts as a negative regulator of VEGF 
signaling pathway. The activation of VEGFR-1 receptor limited trophoblast cell 
DNA synthesis [15], inhibited VEGFR-2 mitogenic activity [16], downregulated 
endothelial cell proliferation [17] and angiogenesis [18]. However, it is not 
clear whether VEGFR-1 homomeric or VEGFR1-2 heteromeric receptor 
mediates the inhibition of VEGFR-2 activity. To dissect the function of 
VEGFR1-2 in endothelial cells, we have generated a unique VEGFR1-2-specific 
ligand VEGF-E:PlGF-1 (VE:Pl) that comprises of one monomer of VEGFR-2-
specific ligand (VEGF-E) and one monomer of VEGFR-1-specific ligand 
(PlGF-1) [19]. A recent study revealed that the VEGF-E:PlGF-1 ligand 
specifically activates heterodimeric VEGFR1-2 to inhibit VEGF-A-induced 
prostacyclin release, phosphorylation of ERK1/2 MAP kinase and mobilization 
of intracellular calcium in endothelial cells [19]. This inhibition is exclusively 
conducted through the VEGFR1-2 heterodimer as VEGF-E:PlGF-1 does not 
activate VEGFR-1 or VEGFR-2 homodimers. We know this to be the case 
because we engineered porcine aortic endothelial (PAE) cells, which do not 
express VEGF receptors, to express either VEGFR-1 or VEGFR-2 [19]. In 
these cells, VEGF-E:PlGF-1 had no effect on VEGF receptor phosphorylation 
[19]. However, both the mechanism of how VEGFR1-2 modulates VEGF 
signaling and the relationship with VEGFR-1 homodimers remain unknown. 
Our novel VEGF-E:PlGF-1 ligand which binds only to the VEGFR1-2  
heterodimer receptor (Fig. 1A) provides the unique opportunity to address the 
role of VEGFR1-2. 
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Although VEGFR-1 signaling activates many pathways including 
phosphatidylinositol-3 kinase (PI3K), Akt, p38, and ERK1/2, PI3K appears to 
be a central regulator in specific cells [20]. Stimulation of VEGF in the cells 
exclusively expressing VEGFR-1 resulted in a strong increase of PI3K/Akt 
phosphorylation [21] and inhibition of VEGFR-1 activity suppressed PI3K-Akt 
signaling in mice [22]. Our previous study showed that VEGFR-1 activates the 
PI3K/Akt pathway to regulate nitric oxide release in endothelial cells [23]. 
Moreover, VEGFR-2 preferentially utilizes the PLCγ-PKC-MAPK pathway, but 
not PI3K/Akt, for signaling, further confirming the preference of PI3K in the 
VEGFR-1 mediated signaling pathway [24]. Therefore, we tested the 
possibility that VEGFR1-2 heterodimer activates PI3K to modulate VEGFR-2 
activity to negatively regulate VEGF signaling in endothelial cells.  
 
In the present study, we demonstrated that the activation of VEGFR1-2 
inhibited, while inhibition of PI3K, promoted VEGFR-2 phosphorylation. 
Furthermore, inhibition of PI3K abrogated the VEGFR1-2 mediated inhibition of 
VEGFR-2 phosphorylation. Finally, we confirmed functionally that the 
activation of VEGFR1-2 significantly suppressed VEGFR-2 induced in vitro 
angiogenesis and this suppression could be abolished by inhibition of PI3K 
pathway.  
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Methods and Materials 
 
 
Reagents and antibodies 
 
Recombinant growth factors, VEGF-A, VEGF-E and PlGF-1, were purchased 
from RELIATech (Brauschweig, Germany). VEGF-E:PlGF-1 was generated in-
house as described previously [19]. LY294002 was purchased from Sigma-
Aldrich (USA).  
   
Rabbit antibodies against phosphorylated VEGF receptor-2 at tyrosine Y951 
and Y1175, phospho-tyrosine of VEGFR-2, phospho ERK1/2 (Thr-202/Tyr-
204), phosphor-Akt (Ser-473), total ERK and Akt were obtained from Cell 
Signaling Technology (Danvers, MA 01923, United States). Rabbit antibodies 
anti-VEGF receptor-1 and 2 were purchased from Santa Cruz Biotechnology 
(Texas, USA). Mouse monoclonal anti-β-Actin antibody was obtained from 
Sigma-Aldrich (A5441, St.Louis, MO, Uinited States). Growth factor reduced 
Matrigel was purchased from Becton Dickinson (Oxford, UK). M199 and Ham 
F-12 medium were purchased from Invitrogen (Paisley, UK). Calcein AM 
Fluorescent Dye was purchased from BD Bioscience (P.O. Box 999 Sparks, 
MD, USA 21152). EZ-ECL kit was purchased from Geneflow Ltd (Staffordshire, 
UK).   
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Cell culture 
 
Human umbilical vein endothelial cells (HUVECs) were purchased from 
Cellworks (Buckingham, UK) and cultured in M199 medium as described 
previously [18]. Experiments were performed on third or fourth passage 
HUVECs. The engineered stable porcine aortic endothelial cells (PAECs) 
containing human VEGF receptor 2 (PAER-2) or both VEGF receptor 1 and 2 
(PAER-1:R-2) were maintained in Ham F-12 supplemented with 10 % FCS 
with the addition of G418 [25].  
 
 
siRNA against VEGFR-1 
 
The small interfering RNA (siRNA) against human VEGFR-1 and a mismatch 
universal control siRNA were described previously [19]. The sequences of 
siRNA duplex to VEGFR-1 are sense, 5′-UGAUGGCCUUACACUGAAAtt-
3′; antisense, 5′-UUUCAGUGUAAGGCCAUCAtt-3′. The non-targeting 
control siRNA (D-001206-13) was purchased from Dharmacon.  
   
 
In vitro cell transfection 
 
The siRNA was transfected into HUVECs using an AMAXA nucleofector 
machine with Primary Endothelial Cells transfection kit (Cat. No. VPI-1001, 
Amaxa).Briefly, HUVECs were trypsinized, and ≈ 1 × 106 cells were 
electroporated with ≈ 3 μ g siVEGFR-1 or control siRNA according to 
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manufacturer’s instructions. Transfected cells were incubated overnight before 
treatment at 37°C incubator.  
 
 
Western Blotting 
 
The procedure for western blot was described previously [26]. Briefly, total 
protein from PAE cells or HUVECs was lysed in RIPA buffer. Protein 
concentration was analyzed using Bradford assay. 30 µg RIPA lysate was 
separated on 8-12 % SDS-PAGE and transferred into Hybond N+ membrane. 
Primary antibody diluted 1:1000 was used to incubate with the membrane for 
4-6 h and then washed with TBS-T buffer three times of 15 mins. Secondary 
antibody diluted 1: 5000-10,000 was used to incubate with the membrane at 
room temperature for 1 h and then followed by three 20 mins washes. Finally, 
the membrane was exposed in a dark room for 1-5 mins using EZ-ECL kit. 
Densitometric analysis was performed across three independent experiments 
using ImageJ software. Protein densitometric levels were normalized to 
respective loading controls.  
 
 
Cell proliferation assay 
Cell proliferation assay was carried out using CyQUANT® NF Cell 
Proliferation Assay Kit (Invitrogen). HUVECs were seeded with a density of 
2000 cells/well in a 96-well plate and rested for overnight. The cells were 
subsequently pre-treated with LY294002, VEGF-E:PlGF-1 alone or in 
combination for 30 minutes. Following pre-treatment, cells were stimulated 
with VEGF-E:PlGF-1 (50 ng/ml), VEGF-E (20 ng/ml) alone or in combination 
for 48-72 hours. The cell number was determined by measuring cellular DNA 
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according to manufacturer’s instruction. Fluorescence density values were 
measured with excitation at 485 nm and emission detection at 530 nm.     
   
 
In vitro tube formation assay 
 
Formation of capillary-like structures on growth factor reduced Matrigel was 
determined as previously described [18]. Briefly, cells (1 x 104 cells/well) were 
seeded onto a Matrigel-coated 96-well plate in culture medium containing 
10% fetal calf serum (FCS). After cells had attached to the Matrigel (1 hours at 
37°C), the FCS containing medium was removed and VEGF-A (20 ng/ml) or 
VEGF-E (20ng/ml) in medium containing 0.2% bovine serum albumin was 
added. After stimulation at 37°C for 6-8 hours, calcein AM Flurorescent Dye 
(BD Bioscience) was added with concentration of 4 µg/ml and incubated in 
37°C for 30 mins for fluorescence microscope observation. Total tube length 
was calculated using Image-Pro plus software and data were collected from 
three independent experiments.  
 
 
Statistical analysis 
 
All data were collected from at least three independent experiments and 
expressed as a mean ± S.E.M. Statistical comparisons were performed using 
Student’s t-test or one-way ANOVA. Statistical significance was set at a value 
of p<0.05. 
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Results 
 
 
Activation of VEGFR1-2 heterodimeric and not VEGFR-
1 homomeric receptor inhibits VEGFR-2 receptor 
phosphorylation  
 
The VEGFR-2 phosphorylation upon VEGF-A stimulation was measured at 
different time points. The phosphorylation of VEGFR-2 was detected 5 
minutes after stimulation and remained for least 15 minutes without a 
significant decrease (Fig. S1). Thus, the following experiments, if not stated 
differently, were performed within a 5 to 10 minute range after growth factor 
stimulation. 
   
To investigate whether deletion of VEGFR-1 affects VEGFR-2 activation, the 
phosphorylation of VEGFR-2 was measured in HUVECs with transfection of 
siVEGFR-1 under the stimulation of VEGF-A. HUVECs transfected with 
siVEGFR-1 showed an increase in phosphorylation at the two major tyrosine 
phosphorylation sites (Y951 and Y1175) in VEGFR-2 compared to the control 
siRNA transfected cells (Fig. 1B). This data implies that the presence of 
VEGFR-1 inhibits VEGFR-2 phosphorylation under VEGF stimulation.  
As knock-down of VEGFR-1 affects both the VEGFR-1 homodimer and 
VEGFR1-2 heterodimer, we further investigated whether the homodimer or 
heterodimer of VEGFR-1 negatively regulates VEGFR-2 phosphorylation. 
HUVECs were pre-treated with PlGF-1 (which only stimulates VEGFR-1 
homodimer, Fig 1A) and subsequently stimulated with a vehicle or VEGF-E. 
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The phosphorylation levels of VEGFR-2 at tyrosine Y951 and Y1175 were 
measured by Western blot. As expected, PlGF-1 treatment did not cause 
phosphorylation of VEGFR-2 (Fig. 1C). Interestingly, cells pre-treated with 
PlGF-1 did not show any difference in VEGFR-2 phosphorylation at both 
tyrosine sites under VEGF-E stimulation compared to VEGF-E only treated 
cells (Fig. 1C).  Therefore it demonstrated that activation of the VEGFR-1 
homodimer does not affect VEGFR-2 phosphorylation. We went on to test 
whether activation of VEGFR1-2 heterodimer negatively regulates VEGFR-2 
phosphorylation using VEGF-E:PlGF-1 ligand (which only activates VEGFR1-2 
heterodimer, Fig 1A). HUVECs were either (i) pre-treated with VEGF-E:PlGF-
1 ligand and then stimulated with VEGF-E; or (ii) simultaneously treated with 
VEGF-E:PlGF-1 and VEGF-E. These conditions were compared to VEGF-E 
only treated cells (Fig. 1D). VEGF-E:PlGF-1 pre-treatment significantly 
reduced VEGFR-2 phosphorylation at both Y951 and Y1175 sites compared 
to cells treated with VEGF-E alone.  Interestingly, simultaneous treatment of 
VEGFE and VEGF-E:PlGF-1 had no inhibitory effect on VEGFR-2 
phosphorylation (Fig. 1D). Notably, the phosphorylation level of VEGFR-2 was 
higher in the VEGF-E:PlGF-1 and VEGF-E co-treated cells compared to 
VEGF-E only treated cells, probably due to the additive effect caused by 
VEGF-E:PlGF-1 (Fig. 1D). Taken together, the data suggest that VEGFR1-2 
rather than VEGFR-1 homomeric receptor negatively regulates VEGFR-2 
phosphorylation (Fig. 1E).  
 
Inhibition of PI3K pathway increases VEGFR-2 
phosphorylation 
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Evidence from earlier studies suggest that the PI3K signaling pathway is 
involved in the downstream signaling of VEGFR-1 to regulate VEGFR-2 
activity [22, 23]. Thus we tested whether inhibition of PI3K could alter the 
phosphorylation level of VEGFR-2 under stimulation of VEGF-A, VEGF-E and 
VEGF-E:PlGF-1 separately or in combination. HUVECs were pre-treated with 
the PI3K inhibitor LY294002 and subsequently treated with VEGF-A. VEGFR-
2 phosphorylation levels at both Y951 and Y1175 sites were significantly 
increased in the cells pre-treated with LY294002 (Fig. 2A).  
 
Since VEGF-A can activate both VEGFR-1 homodimeric and VEGFR1-2 
heterodimeric receptors, we further investigated which receptor was signaling 
through PI3K to prevent VEGFR-2 phosphorylation. As before, HUVECs were 
pre-treated with LY294002 and PlGF-1 separately or in combination. The pre-
treated cells were subsequently stimulated with VEGF-E. Not surprisingly, the 
phosphorylation level of VEGFR-2 in the cells pre-treated with LY294002 and 
PlGF-1 did not show a significant difference compared to cells pre-treated with 
PlGF-1 alone (Fig. 2B). However, VEGF-E stimulation induced a dramatic 
increase in phosphorylation of VEGFR-2 at both Y951 and Y1175 sites in 
HUVECs co-pre-treated with LY294002 and VEGF-E:PlGF-1 compared to 
those only pre-treated with VEGF-E:PlGF-1 (Fig. 2C). This data suggests that 
VEGFR1-2 heterodimeric and not VEGFR-1 homodimer receptor regulate 
VEGFR-2 phosphorylation via PI3K (Fig. 2D).  
 
 
Inhibition of PI3K abrogates the VEGF-E:PlGF-1 
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mediated inhibition of VEGFR-2 signaling 
 
Since our data suggest that VEGFR1-2 heterodimeric receptor regulates 
VEGFR-2 phosphorylation via PI3K, we tested whether inhibition of PI3K 
could abrogate the VEGF-E:PlGF-1 mediated inhibition of VEGFR-2 signaling. 
Firstly, we confirmed that pre-treatment of VEGF-E:PlGF-1 is capable of 
activating PI3K/Akt signaling pathway as measured by Akt (Ser473) 
phosphorylation in endothelial cells (Fig. 3A, 1st panel, red squares). 
Densitometric analysis of phospho-Akt indicated that VEGF-E:PlGF-1 
significantly induced Akt phosphorylation and the addition of LY294002 
dramatically decreased Akt phosphorylation level (P<0.01, Fig. 3B). As 
expected, phosphorylation of VEGFR-2 at Y951 and Y1175 under VEGF-A 
and VEGF-E stimulation was reduced in the HUVECs pre-treated with VEGF-
E:PlGF-1 compared to those without pre-treatment (Fig. 3A, 3rd and 4th 
panels). However, the reduction of VEGFR-2 phosphorylation was abolished, 
at least partially, in the cells additionally pre-treated with LY294002 (Fig. 3A, 
3rd and 4th panels, red square). The densitometric analysis revealed that 
phosphorylation of VEGFR-2 at Y951 and Y1175 in HUVECs co-pre-treated 
with VEGF-E:PlGF-1 and LY294002 was significantly increased compared to 
cells pre-treated with VEGF-E:PlGF-1 under VEGF-A stimulation (P<0.001, 
Fig. 3C and D). Moreover, HUVECs receiving LY294002 pre-treatment also 
exhibited a significant increase in phosphorylation of VEGFR-2 at Y1175 
under VEGF-E stimulation (P=0.0003, Fig. 3D). A similar trend was observed 
on Y951 although not significant (P=0.18, Fig. 3C). Furthermore, we 
examined the level of total phospho-tyrosine of VEGFR-2 under similar 
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treatment conditions. HUVECs pre-treated with VEGF-E:PlGF-1 exhibited a 
notable reduction in total phospho-tyrosine of VEGFR-2 under VEGF-E 
stimulation compared to those without pre-treatment. The inhibition was lost 
when cells were simultaneously stimulated with VEGF-E and VEGF-E:PlGF-1 
(Fig. 3F, red square). As expected, HUVECs which had been co-pre-treated 
with VEGF-E:PlGF-1 and LY294002 showed increased total phospho-tyrosine 
of VEGFR-2 compared to cells pre-treated with VEGF-E:PlGF-1 only (Fig. 3F, 
the 5th and 7th lanes). Taken together, the data implies that tyrosine residues 
on VEGFR-2, including Y951 and Y1175, may be involved in the VEGFR1-2 
mediated inhibition of VEGFR-2 activation.   
 
ERK is the downstream effector in VEGFR-2 mediated signaling [27]. We 
further investigated the ERK phosphorylation under pre-treatment of VEGF-
E:PlGF-1 and LY294002. Phosphorylation of ERK was reduced in the 
HUVECs pre-treated with VEGF-E:PlGF-1 under VEGF-E stimulation 
compared to non-pre-treated cells. The reduction in ERK phosphorylation was 
abrogated by additional pre-treatment with LY294002 (Fig 3A, 6th and 7th 
panel, red square). The densitometric analysis further confirmed that HUVECs 
co-pre-treated with VEGF-E:PlGF-1 and LY294002 showed a significant 
increase in ERK1/2 phosphorylation compared to cells pre-treated with VEGF-
E:PlGF-1 only both under VEGF-A and VEGF-E stimulation (P<0.05, Fig. 3E).   
 
Furthermore, we tested our concept in the PAE cells which were engineered 
to only express VEGFR-2 receptors [19]. PAE-R2 cells co-pre-treated with 
VEGF-E:PlGF-1 and LY294002 did not show a significant difference in the 
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phosphorylation of VEGFR-2 under VEGF-E stimulation compared to VEGF-
E:PlGF-1 pre-treated cells (Fig. 3G). The densitometric analysis also showed 
no significant difference between cells pre-treated with VEGF-E:PlGF-1 and 
LY294002 and those pre-treated with VEGF-E:PlGF-1 only (Fig. 3H). Notably, 
a VEGF-E:PlGF-1 stimulation did not change the phosphorylation level of 
VEGFR-2 compared to vehicle control (Fig. 3G, 1st and 3rd lanes). This data 
confirm that VEGF-E:PlGF-1 does not activate VEGFR-2 homodimers as 
reported earlier [19].  
 
 
Inhibition of PI3K enhances growth factor-mediated 
angiogenesis 
 
Previous data demonstrated that PI3K regulates VEGFR-2 and ERK 
phosphorylation [28, 29]. We therefore tested whether inhibition of PI3K could 
enhance endothelial cell biological function. As a main feature of endothelial 
cells, the in vitro angiogenic ability was investigated in the cells with inhibited 
PI3K. PAER-1:R-2 cells were pre-treated with LY294002 and plated on 
Matrigel under stimulation of VEGF-A (Fig. S2A). The total tube length of cells 
pre-treated with LY294002 was significantly increased compared to non-pre-
treated cells (Fig. S2B), further confirming that inhibition of PI3K could 
enhance endothelial cell biological function.  
 
 
Inhibition of PI3K partially abrogates VEGF-E:PlGF-1 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
16 
 
mediated inhibition of cellular activities  
 
To prove VEGF-E:PlGF-1 acts through PI3K to inhibit VEGFR-2 activity, we 
investigated whether inhibition of PI3K could abrogate the VEGF-E:PlGF-1 
mediated inhibition of VEGFR-2 biological activity in endothelial cells. 
HUVECs were seeded with a density of 2000 cells/well in a 96-well plate and 
pre-treated with LY294002 and VEGF-E:PlGF-1, alone or in combination. 
Following pre-treatment, cells were stimulated with VEGF-E or in combination 
with VEGF-E:PlGF-1 for 48-72 hours. The cell numbers were measured by 
cellular DNA density after stimulation. The cell number in the cells pre-treated 
with VEGF-E:PlGF-1 was significantly reduced compared to cells without pre-
treatment under VEGF-E stimulation (Figure 4A, 3rd and 7th bars). Interestingly, 
the cells simultaneously stimulated with VEGF-E:PlGF-1 and VEGF-E also 
exhibited significant reduction in cell number compared to cells stimulated with 
VEGF-E only (Figure 4A). However, the additional pre-treatment of LY294002 
abrogated the reduction in cell number and increased cell number significantly 
to a level similar to VEGF-E alone stimulated cells (Figure 4A, 3rd and 9th /10th 
bars).      
 
 To further test our theory in angiogenesis, HUVECs were pre-treated with 
VEGF-E:PlGF-1 alone or with LY294002 and subsequently plated on Matrigel 
under stimulation of VEGF-E (Fig. 4B). The total tube length formed in the 
cells pre-treated with VEGF-E:PlGF-1 was decreased under VEGF-E 
stimulation compared to non-pre-treated or VEGF-E:PlGF-1 and VEGF-E 
simultaneously treated cells (Fig. 4C). In line with our hypothesis, HUVECs 
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co-pre-treated with LY294002 and VEGF-E:PlGF-1 showed a significant 
increase in total tube length compared to cells only pre-treated with VEGF-
E:PlGF-1 only under VEGF-E stimulation (Fig. 4C, 5th and 6th bars). The data 
confirmed that inhibition of PI3K by LY294002 restores the tube formation to a 
comparable level to cells treated with VEGF-E and VEGF-E:PlGF-1 
simultaneously (Fig. 4C, the 4th and 6th bars). Interestingly, total tube length in 
the VEGF-E:PlGF-1 and VEGF-E simultaneously treated cells was 
significantly decreased compared to VEGF-E treated cells (P=0.01, Fig. 4C, 
2nd and 4th bars). Notably, the simultaneous treatment of VEGF-E:PlGF-1 and 
VEGF-E did not show an inhibitory effect on VEGFR-2 phosphorylation (Fig. 
1D). The inhibition of tube formation in simultaneously treated cells was 
probably due to the prolonged incubation with VEGF-E:PlGF-1 (6-8 hours to 
5-10 minutes).    
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Discussion 
 
VEGF-A has a lower affinity for VEGFR-2 but this receptor is responsible for 
endothelial cell proliferation and migration [30], whereas VEGFR-1 homomeric 
receptor is reported to negatively regulate VEGF signaling [15, 16, 17, 18]. 
The density of VEGFR-1 on the cell surface is less than tenfold compares to 
those of VEGFR-2 [31] and therefore the majority of VEGFR-1 subunits form 
VEGFR1-2 heteromeric receptors [32]. The role of VEGF signaling via the 
VEGFR1-2 has eluded us due to the lack of a ligand that specifically binds to 
VEGFR1-2 receptor. The generation of VEGF-E:PlGF-1 ligand by our group 
provided the opportunity to dissertate the VEGFR1-2 receptor function [19]. To 
the best of our knowledge, this study demonstrated for the first time that 
activation of VEGFR1-2 decreased VEGFR-2 phosphorylation under VEGF 
stimulation. This is the first direct evidence to demonstrate the interplay 
between VEGFR-1 and VEGFR-2 receptor-mediated signaling pathways in 
endothelial cells. It has been demonstrated that VEGF, through VEGFR-1 
stimulates PI3K [21, 33, 34, 35]. However it is not clear whether PI3K is 
activated by VEGFR-1 homomeric receptor or VEGFR1-2 heteromeric receptor. 
In this study, we identified that VEGFR1-2 receptor and not VEGFR-1 
homomeric receptor activates PI3K to suppress VEGFR-2 receptor activity 
and the inhibition of PI3K could restore the VEGFR1-2 receptor mediated 
inhibition of VEGFR-2 activity.  
 
The mechanism by which VEGFR1-2 inhibits VEGFR-2 activity is still not clear. 
Our study confirms the ability of VEGFR1-2 itself to induce biological signaling 
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and activities (Fig. 4A) [19]. However, it is not clear whether VEGFR1-2 inhibits 
VEGFR-2 signaling through its downstream effector or direct interaction. Our 
present study implies that VEGFR1-2 regulates VEGFR-2 signaling through an 
indirect rather than direct interaction since only pretreatment of VEGF-E:PlGF-
1 is able to inhibit VEGFR-2 phosphorylation (Fig. 1D). Notably, the 
simultaneous stimulation of VEGF-E:PlGF-1 and VEGF-E leads to higher 
VEGFR-2 phosphorylation compared to VEGF-E only treatment (Fig. 1D). The 
loss of inhibition on VEGFR-2 phosphorylation by VEGF-E:PlGF-1 is probably 
due to the short duration (5-10 minutes) stimulation which is not enough to 
trigger the downstream effectors. Indeed, the simultaneously addition of 
VEGF-E:PlGF-1 and VEGF-E in a relative long experiment setting, such as 
tube formation and cell proliferation (6-8 and 48-72 hours), did inhibit VEGF-E 
mediated biological activity (Fig. 4A and B). Moreover, our data highlights the 
possibility of PI3K in the inhibition of VEGFR-2 signaling. However, PI3K is 
also demonstrated to play an important role in regulating endothelial 
proliferation, migration and survival through VEGFR-2 signaling [36, 37]. Thus, 
the PI3K pathway may play a complex role in the regulation of VEGF signaling. 
As mentioned earlier, only cells that received a pre-treatment of VEGF-
E:PlGF-1 exhibited an inhibitory effect and not in the cells simultaneously 
treated with VEGF and VEGF-E:PlGF-1. This observation further implies that 
temporal activation of PI3K may affect its subsequent biological activity. In line 
with this, the spatial and temporal regulation of PI3K is demonstrated to be 
required for proper chemotaxis and hematopoietic stem cell maintenance [38, 
39]. In addtion, the pretreatment of VEGF-E:PlGF-1 may also lead to the rapid 
internalization and endocytosis of cell surface VEGFR-2 receptor thus 
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inhibiting VEGF mediated biological activity. Our previous study demonstrated 
the rapid internalization and trafficking of VEGFR-2 receptor upon VEGF-
E:PlGF-1 stimulation [19]. Other studies also confirmed that VEGF receptor 
internalization and endocytosis is required for endothelial cell biological 
functions, such as ERK1/2 activation [40], angiogenesis [41] and cell recovery 
after wounding [42]. To gain a better understanding of VEGFR1-2 biological 
function, further investigation is warranted.        
  
Anti-VEGF therapies via neutralizing VEGF ligand or VEGFR-2 inhibition are 
in use but effectiveness in cancer treatment is limited [43, 44]. Likewise, 
therapeutic angiogenesis used to treat limb ischemia [45], peripheral artery 
[46] and coronary artery disease [47] by promoting VEGF signaling have not 
been a great success and clinical trials are inconclusive [48, 49]. This is 
thought to be due to possible “off-target” effects of the currently available 
VEGF pathway activators and inhibitors [50]. Our study highlights that the role 
of VEGFR1-2 in the regulation of VEGF signaling should be considered when 
designing agents which regulate VEGF receptor activity. The agents that 
regulate VEGFR-2 receptor might also target VEGFR1-2 heterodimeric 
receptor and subsequently disrupt the natural inhibitory mechanisms designed 
to regulate VEGFR-2 activity.  
 
In conclusion, our data demonstrates that VEGFR1-2 heteromeric receptor and 
not VEGFR-1 homomeric receptor is responsible for limiting VEGF signaling 
through downregulation of VEGFR-2 phosphorylation and thus attenuates 
VEGFR-2 activity. Furthermore, we confirmed that PI3K pathway acts 
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downstream of VEGFR1-2 receptor and inhibition of PI3K abrogates VEGFR1-2 
mediated inhibition of VEGF signaling. VEGFR1-2 receptor and the 
downstream PI3K pathway may serve as new targets to modulate VEGF 
pathway activity in vascular disorders. 
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Figure Legends 
 
 
Figure 1. VEGFR1-2 heteroreceptor, but not VEGFR-1 homoreceptor, 
negatively regulates VEGFR-2 phosphorylation. (A) Schematic diagram 
showing VEGF signalling pathway. Red bar represents VEGFR-2 receptor 
and black bar represents VEGFR-1 receptor.  (B) HUVECs were 
electroporated with siRNA against VEGFR-1 (siR-1) and subsequently 
stimulated with VEGF-A (20 ng/ml) after 24 hour recovery. The protein lysates 
were collected 5-10 min after vehicle or VEGF-A stimulation and assayed with 
western blot using antibodies against phosphorylated VEGFR-2 at Y951 and 
Y1175 sites, total VEGFR-2, total VEGFR-1 and beta-actin.  (C)  HUVECs 
were stimulated for 5-10 min with VEGF-A (20 ng/ml), PlGF-1 (50 ng/ml), 
VEGF-E (20 ng/ml) or pre-treated with PlGF-1 for 30 min (Pre) and 
subsequently stimulated with VEGF-E. Cell lysates were western blotted for 
phosphorylated VEGFR-2 at Y951 and Y1175 sites, total VEGFR-2 and beta-
actin. (D) HUVECs were stimulated for 5-10 min with VEGF-E:PlGF-1 (VE:Pl, 
50 ng/ml), VEGF-E (20 ng/ml), VEGF-E plus VEGF-E:PlGF-1 simultaneously 
(Sim) or pre-treated for 30 min (Pre).  Cell lysates were western blotted for 
phosphorylated VEGFR-2 at Y951 and Y1175 sites, total VEGFR-2 and beta-
actin. (E) Schematic diagram showing VEGFR1-2 heteroreceptor negatively 
regulates VEGFR-2 phosphorylation. Sim, simultaneously stimulation (added 
together); Pre, pre-treatment as described. Data were collected from three 
independent experiments.  
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Figure 2. Inhibition of PI3K increases VEGFR-2 phosphorylation. (A) 
HUVECs were pre-treated with LY294002 (20uM) for 30 min and 
subsequently treated with vehicle or VEGF-A (20 ng/ml) for 5-10 min. Cell 
lysates were collected and assayed for western blot using antibodies against 
phosphorylated VEGFR-2 at Y951 and Y1175 sites, total VEGFR-2 and beta-
actin. (B) HUEVCs were pre-treated with LY294002 (20uM) or in combination 
with PlGF-1 (Pre, 50ng/ml) for 30 min and subsequently stimulated with 
VEGF-E (20ng/ml) for 5-10 min. Cell lysates were western blotted with 
antibodies against phosphorylated VEGFR-2 at Y951 and Y1175 sites, total 
VEGFR-2 and beta-actin. (C) HUVECs were pre-treated with LY294002 
(20uM) alone or in combination with VEGF-E:PlGF-1 (VE:Pl, Pre, 50ng/ml) for 
30 min and subsequently stimulated with VEGF-E (20ng/ml) for 5-10 min. Cell 
lysates were western blotted with antibodies against phosphorylated VEGFR-
2 at Y951 and Y1175 sites, total VEGFR-2 and beta-actin. (D) Schematic 
diagram showing VEGF-R1:R2 heteroreceptor through PI3K pathway to 
negatively regulates VEGFR-2 phosphorylation. Data were collected from 
three independent experiments.  
 
 
Figure 3. Inhibition of PI3K abrogates VEGF-E:PlGF-1 mediated 
inhibition of VEGFR-2 phosphorylation. (A) HUVECs were pre-treated with 
LY294002, VEGF-E:PlGF-1 (VE:Pl) alone or in combination for 30 min (Pre) 
and subsequently stimulated with vehicle, VEGF-A or VEGF-E for 5-10 min. 
Cell lysates were blotted with antibodies against phospho-AKT(Ser473), total 
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AKT, phosphorylated VEGFR-2 at Y951 and Y1175 sites, total VEGFR-2, 
phospho-ERK (at 2 min and 10 min exposure), total ERK and beat-actin. (B, C, 
D, E) Densitometric analysis of phospho-Akt to total Akt, VEGFR-2 
phosphorylation at Y951 and Y1175 to total VEGFR-2 and ERK1/2 
phosphorylation to total ERK shown in A. (F) HUVECs were pre-treated with 
VEGF-E:PlGF-1 alone or in combination with LY294002 for 30 min (Pre) and 
subsequently stimulated with VEGF-E. Alternatively, cells were stimulated 
simultaneously without pre-treatment (Sim) with VEGF-E in combination with 
VEGF-E:PlGF-1 and/or LY294002 for 5-10 min. Cell lysates were western 
blotted with antibodies against total phospho-tyrosine of VEGFR-2, total 
VEGFR-2 and beta-actin. (G) PAE-R2 cells were pre-treated with VEGF-
E:PlGF-1 or in combination with LY294002 for 30 min (Pre) and subsequently 
stimulated with VEGF-E or stimulated simultaneously with VEGF-E in 
combination with VEGF-E:PlGF-1 and/or with LY294002 (Sim) for 5-10 min. 
Cell lysates were blotted with antibodies against phosphorylated VEGFR-2 at 
Y951 and Y1175 sites, total VEGFR-2 and beta-actin. (H) Densitometric 
analysis of VEGFR-2 phosphorylation to total VEGFR-2 shown in G. Data 
were collected from three independent experiments.  
 
 
Figure 4. Inhibition of PI3K pathway rescues VEGF-E:PlGF-1 mediated 
inhibition of cellular activities. (A) HUVECs were seeded with a density of 
2000 cells/well in a 96-well plate and pre-treated with LY294002 and VEGF-
E:PlGF-1 (VE:Pl), alone or in combination (Pre). The pre-treated cells were 
then stimulated with VEGF-E or in combination with VEGF-E:PlGF-1 (Sim) for 
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48-72 hours. The cell numbers were measured using CyQUANT® NF cell 
proliferation assay kit (Invitrogen) following the manufacturer's instructions. (B) 
HUVECs were pre-treated with LY294002, VEGF-E:PlGF-1 alone or in 
combination for 30 min (Pre) and subsequently used for capillary-like tube 
formation assay under VEGF-E stimulation. Alternatively, HUVECs were 
directly used for tube formation assay under stimulation of VEGF-E or in 
combination with VEGF-E:PlGF-1 simultaneously without pre-treatment (Sim). 
Representative fluorescence images of tubular structure were taken after 6-8h 
incubation. (C) The quantification of mean total tube length per X4 field was 
performed using Image-Pro Plus software. Data are expressed as 
representative of mean ± SEM of three or more independent experiments 
performed in triplicate. Scale bar, 250 µm.  
 
S1 Fig. The phosphorylation of VEGFR-2 upon VEGF-A stimulation in 
endothelial cells. (A) HUVECs were stimulated with VEGF-A (20ng/ml) and 
the phosphorylation of VEGFR-2 of Y951 was measured at 0, 5 and 15 
minutes after the stimulation by western blotting.   
 
 
S2 Fig. Inhibition of PI3K promotes in vitro tube formation in endothelial 
cells. (A) PAE-R1:R2 cells were pre-treated with LY294002 for 30 minutes 
and subsequently used for capillary-like tube formation assay under 
stimulation of VEGF-A in a 96-well plate. Representative images of tubular 
structure were taken after 6-8h incubation. (B) The quantification of mean total 
tube length per X10 field was performed using Image-Pro Plus software. Data 
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are expressed as mean ± SEM of three or more independent experiments 
performed in triplicate. Scale bar, 25 µm. 
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